

## AstraZeneca (UK): Acquisition of Alexion Pharmaceuticals (USA) Changes in FTSE RAFI™ Index Series

15 July 2021

Subject to the completion of the cash and stock acquisition of Alexion Pharmaceuticals (USA, constituent) by AstraZeneca (UK, constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE RAFI Developed ex US 1000	21 July 2021
FTSE RAFI Developed ex US 1000 Index - QSR	21 July 2021
FTSE RAFI All World 3000 Index	21 July 2021
FTSE RAFI All World 3000 Index - QSR	21 July 2021
FTSE RAFI Developed 1000 Index	21 July 2021
FTSE RAFI Developed 1000 Index - QSR	21 July 2021
FTSE RAFI US 1000 Index	21 July 2021
FTSE RAFI US 1000 Index - QSR	21 July 2021
FTSE RAFI Kaigai 1000 Index	21 July 2021

\*The number of shares is based on the acquisition terms of 2.1243 Astrazeneca ADS, where each ADS represents half an ordinary share, for every Alexion Pharmaceuticals share held.

For further information please contact FTSE Russell Client Services at [info@ftserussell.com](mailto:info@ftserussell.com) or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at [www.ftserussell.com](http://www.ftserussell.com)

Terms of Use | Copyright © 2021 FTSE Russell